Search

Your search keyword '"Seguier, Julie"' showing total 26 results
Start Over Author "Seguier, Julie" Publication Type Academic Journals
26 results on '"Seguier, Julie"'

1. Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL)

Author

Grobost, Vincent, Hammi, Sami, Pereira, Bruno, Guilhem, Alexandre, Duffau, Pierre, Seguier, Julie, Parrot, Antoine, Gautier, Giovanni, Alric, Laurent, Kerjouan, Mallorie, Le Guillou, Xavier, Simon, Delphine, Chaussavoine, Laurent, Rondeau-Lutz, Murielle, Leguy-Seguin, Vanessa, Delagrange, Laura, Lavigne, Christian, Maillard, Hélène, and Dupuis-Girod, Sophie

Published
2023
Full Text
View/download PDF

2. Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT

Author

Le, Thi Thao Truc, Martinent, Guillaume, Dupuis-Girod, Sophie, Parrot, Antoine, Contis, Anne, Riviere, Sophie, Chinet, Thierry, Grobost, Vincent, Espitia, Olivier, Dussardier-Gilbert, Brigitte, Alric, Laurent, Armengol, Guillaume, Maillard, Hélène, Leguy-Seguin, Vanessa, Leroy, Sylvie, Rondeau-Lutz, Murielle, Lavigne, Christian, Mohamed, Shirine, Chaussavoine, Laurent, Magro, Pascal, Seguier, Julie, Kerjouan, Mallorie, and Fourdrinoy, Sylvie

Published
2022
Full Text
View/download PDF

5. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Author

Aeschlimann, Florence, Agard, Christian, Ait-Abdallah, Nassim, Albert, Jean-David, Alcais, Didier, Allain, Jean-Sébastien, Allanore, Yannick, Amador-Borreiro, Blanca, Amoura, Zahir, Andre, Emma, Arbault, Anaïs, Arlet, Jean-Benoît, Arnaud, Laurent, Arniaud, Denis, Arty-Hue, Herliette, Atlan, Lucie, Audemard-Verger, Alexandra, Audoin-Pajot, Christine, Audren, Victor, Bach-Bunner, Maxime, Bacquet-Deschryver, Hélène, Bader-Meunier, Brigitte, Balandraud, Nathalie, Balblanc, Jean-Charles, Bally, Stéphane, Banal, Frédéric, Barbery, Pierre, Barnetche, Thomas, Barrelet, Audre, Basch, André, Baumier, Vincent, Bayer, Guillaume, Bayle, Sophie, Beauvais, Catherine, Beinat, Rudie, Belin, Véronique, Belkhir, Rakiba, Benainous, Ruben, Belot, Alexandre, Benammar, Mohammed, Benhamou, Mathilde, Benhamou, Ygal, Benmansour, Ahmed, Bennet, Pascal, Bernoux-Manat, Brigitte, Berthet, Elise, Berthoux, Emilie, Bertolini, Ewa, Bigot, Adrien, Bisson-Vaivre, Aurélia, Blaison, Gilles, Bolla, Gilles, Bonidan, Olivier, Bonnet, Christine, Borie, Raphaël, Bossert, Marie, Boudou, Laurence, Bouhour, Françoise, Bouiller, Kévin, Bouldoires, Bastien, Boussoualim, Karima, Bouvard, Eric, Brondino, Regine, Buchlin, Pierre, Cabantous, Laurence, Cacoub, Patrice, Cadiou, Simon, Carteni, Maurizio, Carbasse, Aurélia, Castel, Brice, Cathebras, Pascal, Caumont, Hervé, Celant, Annalisa, Chaigne, Benjamin, Chaillous, Benoît, Champy, Romuald, Charcot, Agnès, Charles, Pierre, Charlot-Lambrecht, Isabelle, Charpin, Caroline, Chatelus, Emmanuel, Chaudier, Bernard, Chertok, Pascale, Chevalier, Xavier, Chevreau, Maxime, Chotard, Emilie, Chu Miow Lin, Delphine, Clavel, Gaëlle, Clavel-Osorio, Cyril, Cohen, Fleur, Cohen, Gregory, Colette-Cedoz, Marie-Eve, Collercandy, Nived, Colombey, Antoine, Comarmond, Chloé, Combe, Bernard, Comparon, Céline, Constant, Elodie, Coquerelle, Pascal, Corli, Justine, Corre, Clémence, Costedoat-Chalumeau, Nathalie, Couret, Marie, Courvoisier, Natacha, Coury-Lucas, Fabienne, Coutarel, Cécile, Coutier, Fabrice, Damade, Richard, Daver-Malaterre, Laurence, Dehimat, Sarahe, Delahousse, Michel, Barrois-Delattre, Emilie, Denarie, Delphine, Deprouw, Camille, Dernis, Emanuelle, Deroux, Alban, Desbarbieux, Renaud, Descamps, Elise, Deslandre, Chantal, Desmurs, Marie, Despaux, Jacques, Desplats, Marie, Detree, Frédérick, Devauchelle-Pensec, Valérie, Dhote, Robin, Dieude, Philippe, Dieudonne, Yannick, Diot, Elisabeth, Direz, Guillaume, Djeddi, Djamal-Dine, Douvier, Sarah, Drouet, Béatrice, Drumez, Elodie, Duc, Catherine, Ducornet, Angélique, Dufauret-Lombard, Carine, Duhamel, Alain, Dumaine, Cécile, Dumel, Anne-Elisabeth, Dumoulin-Richez, Chantal, Duquesne, Agnès, Durand, Géraldine, Durandin-Truffinet, Mariane, Duret, Pierre-Marie, Duval, Maïka, Ebbo, Mikaël, Ebstein, Esther, Economu-Dubosc, Andra, Emilie, Stéphanie, Euvrard, Romain, Evon, Philippe, Fabre, Sylvie, Fagedet, Dorothée, Farhat, Meryem, Fauconier, Marion, Fechtenbaum, Jacques, Felten, Renaud, Fernandes, Fanny, Ferreira-Maldent, Nicole, Feurer, Elodie, Fichet, Amandine, Flaisler, Françoise, Florens, Nans, Foltz, Violaine, Fontanges, Elisabeth, Foret, Jennifer, Fougerousse, Anne-Claire, Fouque-Aubert, Anne, Foutrier-Morello, Catherine, Francois-Pradier, Hélène, Frantzen, Léa, Fritz, Pierre, Froissart, Antoine, Fulpin, Jean, Fuzibet, Piera, Gaches, Francis, Gagneux-Lemoussu, Laurence, Penhoat-Gahier, Mélanie, Galland, Joris, Gandjbakhch, Frédérique, Garnier, Nicole, Garraud, Thomas, Garrot, Jean-François, Gastaldi, Romain, Gaud-Listrat, Véronique, Gauthier-Prieur, Maud, Georgescu, Dana, Gerard, Nathalie, Gervais, Elisabeth, Gibert, Christelle, Gibert, Eric, Gill, Ghislaine, Gillard, Jérôme, Gilson, Mélanie, Gimonnet, Pauline, Giraudet-Le Quintrec, Jeanine-Sophie, Giraud-Morelet, Aude, Glace, Baptiste, Glanowski, Camille, Godeau, Bertrand, Gombert, Bruno, Gonnet-Gracia, Camille, Goulenok, Tiphaine, Goupille, Philippe, Gourmelen, Olivier, Govindaraju-Audouard, Sophie, Grados, Franck, Grall-Lerosey, Martine, Grardel, Bruno, Grasland, Anne, Grateau, Gilles, Groza, Monica, Guillaud, Constance, Guillaume, Séverine, Guillibert, Caroline, Guillot, Xavier, Guilpain, Philippe, Gury, Aline, Guyot, Marie-Hélène, Hacquard-Bouder, Cécile, Havard, Marie-Noelle, Hellier, Jean-Pierre, Hennequin, Pascal, Henriot, Basile, Henry, Julien, Hentgen, Véronique, Hermet, Marion, Herasse, Muriel, Hernandez, Julie, Hie, Miguel, Hilliquin, Pascal, Hinschberger, Olivier, Hittinger-Roux, Ambre, Holubar, Jan, Hudry, Christophe, Huguenel, Serge, Jaccard, Clara, Jacquemier, Jean-Michel, Jamard, Bénédicte, Jan, Catherine, Jean, Sylvie, Jouvray, Mathieu, Juge, Pierre-Antoine, Juillard, Laurent, Jullien, Denis, Kabala, Anna, Kabchou, Abdelkrim, Karkowski, Ludovic, Karman, Françoise, Kemiche, Farid, Keraen, Jérémy, Kieffer, Pierre, Kone-Paut, Isabelle, Koreichi, Abdeldajallil, Kostine, Marie, La Batide Alanore, Sylvain, Lafforgue, Pierre, Lahalle, Sophie, Lambert, Marc, Lambrecht, Isabelle, Lanot, Sylvain, Lanteri, Aurélia, Larbre, Jean-Paul, Latourte, Augustin, Lavigne, Christian, Le Guen Guegan, Sophie, Le Guenno, Guillaume, Leguy, Diane, Lebrun, Agnès, Ledoult, Emmanuel, Legoupil, Nathalie, Legrand, Erick, Lejeune, Charlotte, Leloire, Olivier, Leroux, Christophe, Leroy, Rémi, Leroy-Gouix, Marie, Leturcq, Tifenn, Leurs, Amélie, Leveque-Michaud, Céline, Limbach, François-Xavier, Liote, Frédéric, Lohse, Anne, Lozac'h, Pierre, Lucas, Virginie, Madelon, Aurélie, Magy-Bertrand, Nadine, Mahevas, Matthieu, Maillard, Hélène, Maillet, Thibault, Malochet-Guinamand, Sandrine, Mangon, Quentin, Marchou-Lopez, Sylvie, Margarit, Nathalie, Marhadour, Thierry, Mariette, Xavier, Martin, Claire, Mathian, Alexis, Maurier, François, Maury, Frédéric, Mazet-Guillaume, Betty, Mazouyez, Arnaud, Mazyad, Hassan, Mehsen-Cetre, Nadia, Meinzer, Ulrich, Melki, Isabelle, Messer, Laurent, Miceli, Corinne, Michaud, Martin, Michel, Catherine, Michel, Matthias, Michon, Mathilde, Milesi-Lecat, Anne-Marie, Molto, Anna, Moly, Marie, Moranne, Olivier, Morel, Gautier, Morel, Hugo, Morel, Jacques, Morin, Franck, Moulinier, Laurence, Moulis, Guillaume, Moura, Bertrand, Nguyen, Minh, Nicolas-Vullierme, Sabine, Nielly, Hubert, Nocturne, Gaétane, Nottez, Aurore, Ollagnon, Henri-Olivier, Pacaud-Vitoux, Isabelle, Pagnier, Anne, Paris, Caroline, Parrot, Antoine, Pascart, Tristan, Pascaud-Mansour, Yasmina, Paulin, Lætitia, Pavy, Stephan, Perard, Laurent, Pers, Yves-Marie, Pha, Micheline, Pichon, Maud, Pierreisnard, Audrey, Pizana, Gabrielle, Poignant, Sylvaine, Poix, Elsa, Portier, Agnès, Poulet, Antoine, Plassard, Samira, Pugnet, Grégory, Puyraimond-Zemmour, Déborah, Quartier-Dit-Maire, Pierre, Quenet, Marion, Queyrel, Viviane, Raffray, Loïc, Remy, Philippe, Renard, Myriam, Rene, Jessica, Revuz, Sabine, Rey, Bénédicte, Richard-Colmant, Gaëlle, Riviere, Etienne, Riviere, Sébastien, Robin, Sophie, Rohmer, Julien, Roitg, Isabelle, Romier, Mélanie, Rolland, Michel, Roriz, Mélanie, Rosenberg, Carole, Rossi, Linda, Roth, Olivier, Rouidi, Sid-Ahmed, Roumier, Mathilde, Rousiere, Mickaël, Rousselin, Clémentine, Rouviere, Bénédicte, Roux, Christian, Roux, Fabienne, Roux, Marielle, Roux, Nicolas, Rouzaud, Diane, Rozenberg, Sylvie, Sacco, Isabelle, Sadji, Fatiha, Sailler, Laurent, Salliot, Carine, Salmon, Jean-Hugues, Saraux, Alain, Schmidt, Jean, Seguier, Julie, Sellam, Jérémie, Senbel, Eric, Sene, Thomas, Senet, Patricia, Seve, Pascal, Sicaud, Aurélie, Smets, Perrine, Sobanski, Vincent, Sordet, Christelle, Sornay-Rendu, Elisabeth, Souchaud-Debouverie, Odile, Sparsa, Lætitia, Spielmann, Lionel, Steib, Sarah, Stavris, Chloé, Straus, Catherine, Strotz, Victor, Szafors, Paulina, Taffignon-Clave, Séverine, Simoens, Justine, Theillac, Claire, Tenenbaum, Nora, Thomachot, Benoît, Tieulie, Nathalie, Tiriau, Soizic, Tison, Alice, Toussirot, Eric, Trefond, Ludovic, Trijau, Sophie, Trouillier, Sébastien, Trouvin, Anne-Priscille, Truchetet, Marie-Elise, Ulrich, Marc, Vaquier, Jacques, Veillard, Eric, Veillon, Laurent, Vial, Guillaume, Viallard, Jean-François, Victor, Judith, Vidon, Claire, Vidon, Mathias, Vigne, Camille, Virone, Alexandre, Warzocha, Ursula, Wendling, Daniel, Werle, Claude, Wibaux, Cécile, Willems, Alexandra, Wisniewski, Michel, Woessner, Juliette, Xerri-Campano, Bernadette, Avouac, Jérôme, Hachulla, Eric, Seror, Raphaèle, Georgin-Lavialle, Sophie, El Mahou, Soumaya, Pertuiset, Edouard, Pham, Thao, Marotte, Hubert, Servettaz, Amélie, Domont, Fanny, Chazerain, Pascal, Devaux, Mathilde, Claudepierre, Pascal, Langlois, Vincent, Mekinian, Arsène, Maria, Alexandre Thibault Jacques, Banneville, Béatrice, Fautrel, Bruno, Pouchot, Jacques, Thomas, Thierry, Flipo, René-Marc, and Richez, Christophe

Published
2021
Full Text
View/download PDF

7. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study

Author

Roupie, Anne Laure, Guedon, Alexis, Terrier, Benjamin, Lahuna, Constance, Jachiet, Vincent, Regent, Alexis, de Boysson, Hubert, Carrat, Fabrice, Seguier, Julie, Terriou, Louis, Versini, Mathilde, Queyrel, Viviane, Groh, Matthieu, Benhamou, Ygal, Maurier, Francois, Ledoult, Emmanuel, Clech, Lenaig Le, D'Aveni, Maud, Rossignol, Julien, Galland, Joris, Willems, Lise, Chiche, Noemie Jourde, Peterlin, Pierre, Roux-Sauvat, Marielle, Parcelier, Anne, Wemeau, Matthieu, Lambert, Marc, Belizna, Cristina, Puechal, Xavier, Swiader, Laure, Cohen-Valensi, Rolande, Noc, Valérie, Dao, Emmanuel, Thepot, Sylvain, de Frémont, Grégoire Martin, Tanguy-Schmidt, Aline, Koka, Anne Marfaing, Bussone, Guillaume, Philipponnet, Carole, Konate, Amadou, Cavaille, Guilhem, Guilpain, Philippe, Allain, Jean-Sébastien, Broner, Jonathan, Solary, Eric, Ruivard, Marc, de Renzis, Benoit, Corm, Sélim, Baati, Nadia, Schleinitz, Nicolas, Ponsoye, Matthieu, Stamatoullas-Bastard, Aspasia, Ades, Lionel, Dellal, Azeddine, Tchirkov, Andrei, Aouba, Achille, Fenaux, Pierre, Fain, Olivier, and Mekinian, Arsène

Published
2020
Full Text
View/download PDF

9. Clinical presentation, treatment and outcome of IgG4-related pachymeningitis: From a national case registry and literature review

Author

Melenotte, Cléa, Seguier, Julie, Ebbo, Mikael, Kaphan, Elsa, Bernit, Emmanuelle, Saillier, Laurent, Audoin, Bertrand, Feyeux, Delphine, Daniel, Laurent, Roche, Pierre-Hugues, Graillon, Thomas, Dufour, Henry, Boutière, Clémence, Girard, Nadine, Closs-Prophette, Fabienne, Guillaud, Constance, Tieulié, Nathalie, Regent, Alexis, Harlé, Jean Robert, Hamidou, Mohamed, Mekinian, Arsène, Grados, Aurélie, and Schleinitz, Nicolas

Published
2019
Full Text
View/download PDF

11. The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France

Author

Ackermann, Felix, Adoue, Daniel, Alexandra, Jean-François, Alric, Laurent, Andre, Baptiste, Arista, Sophie, Astudillo, Leonardo, Audia, Sylvain, Badet, Françoise, Balardy, Laurent, Berezne, Alice, Bonmati, Caroline, Bonnet, Delphine, Borel, Cécile, Bories, Eva, Bouillet, Laurence, Boutboul, David, Branco, Benoit, Brechemier, Delphine, Briantais, Antoine, Brun, Natacha, Carreiro, Miguel, Castel, Brice, Cathebras, Pascal, Catros, Florian, Caubet, Olivier, Caudrelier, Léo, Chaminade, Axel, Chauveheid, Marie-Paul, Cheze, Stéphane, Chezel, Julie, Clement, Mélissa, Comont, Thibault, Corvilain, Emilie, Cougoul, Pierre, Courtault, Carine, Crickx, Etienne, Damian, Louise, De Almeida, Sébastien, de Sainte Marie, Benjamin, Decker, Paul, Deibener-Kaminsky, Joëlle, Delavigne, Karen, Delbrel, Xavier, Denis, Guillaume, Deshayes, Samuel, Dingremont, Claire, Dion, Jérémie, Dossier, Antoine, Duffau, Pierre, Dumont, Anne, Dupont, Romain, Durand, Jean-Marc, Ebbo, Mikael, Eshagh, Deborah, Fadlallah, Jehane, Farhat, Meryem, Faucher, Benoit, Faurie, Pierre, Faurie, Thomas, Fieschi, Claire, Galicier, Lionel, Garric, Marie, Gaudin, Clément, Gauthier, Martin, Gerfaud-Valentin, Mathieu, Ghrenassia, Etienne, Giraud, Jean-Thomas, Gobert, Delphine, Godel-Labouret, Aurélie, Goulenok, Tiphaine, Gourguechon, Clément, Goursaud, Laure, Graveleau, Julie, Grobost, Vincent, Guilpain, Philippe, Hadj-Khelifa, Sondess, Harle, Jean-Robert, Hebraud, Benjamin, Hennique, Hélène, Hot, Arnaud, Issaka, Ismaël, Jaussaud, Roland, Jean, Estelle, Jeandel, Pierre-Yves, Khatibi, Sarah, Kouchit, Yanis, Laribi, Kamel, Lazareth, Anne, Lechtman, Sarah, Leguenno, Guillaume, Lemeu, Mélanie, Lemonnier, Margaux, Leplay, Lorraine, Leveneur, Yann, Levraut, Michael, Lifermann, François, Limal, Nicolas, Lioger, Bertrand, Lobbes, Hervé, Loustau, Valentine, Machelart, Irène, Madaule, Serge, Mahevas, Matthieu, Maigne, Gwenola, Malphettes, Marion, Maquet, Julien, Martin-Blondel, Guillaume, Martis, Nihal, Merckx, Antoine, Michaud, Martin, Mohamed, Shirine, Moignet-Autrel, Aline, Montes, Lydia, Moulinet, Thomas, Mourguet, Morgane, Nuccio, Fanny, Orvain, Corentin, Pan Petesch, Brigitte, Papo, Thomas, Paricaud, Kim, Pastissier, Andréa, Perard, Laurent, Piel-Julian, Marie-Léa, Pinede, Laurent, Pontille, Fabien, Prudhomme, Laurent, Pugnet, Grégory, Quinquenel, Anne, Rauzy, Odile, Recher, Christian, Remy, Véronique, Reynaud, Quitterie, Rieu, Virginie, Rigal, Florence, Rispal, Patrick, Rivet, Valérian, Robbins, Ailsa, Rohmer, Julien, Roumier, Mathilde, Ruivard, Marc, Saada, Noemie, Sacre, Karim, Sailler, Laurent, Saint-Lezer, Arnaud, Saunier, Aurélie, Sauvetre, Gaetan, Schleinitz, Nicolas, Seguier, Julie, Sire, Stéphane, Soubrier, Caroline, Swiader, Laure, Tavitian, Suzanne, Terriou, Louis, Thomazeau, Josephine, Toledano, Albanie, Urbanski, Geoffrey, Veit, Véronique, Versini, Mathilde, Viallard, Jean-François, Walter, Ondine, Moulis, Guillaume, Michel, Marc, Bonnotte, Bernard, and Godeau, Bertrand

Published
2024
Full Text
View/download PDF

14. Seven cases of hereditary haemorrhagic telangiectasia-like hepatic vascular abnormalities associated with EPHB4 pathogenic variants.

Author

Guilhem, Alexandre, Dupuis-Girod, Sophie, Espitia, Olivier, Rivière, Sophie, Seguier, Julie, Kerjouan, Mallorie, Lavigne, Christian, Maillard, Hélène, Magro, Pascal, Alric, Laurent, Lipsker, Dan, Parrot, Antoine, Leguy, Vanessa, Vanlemmens, Claire, Guibaud, Laurent, Vikkula, Miikka, Eyries, Melanie, Valette, Pierre-Jean, and Giraud, Sophie

Abstract

Background EPHB4 loss of function is associated with type 2 capillary malformation–arteriovenous malformation syndrome, an autosomal dominant vascular disorder. The phenotype partially overlaps with hereditary haemorrhagic telangiectasia (HHT) due to epistaxis, telangiectases and cerebral arteriovenous malformations, but a similar liver involvement has never been described. Methods Members of the French HHT network reported their cases of EPHB4 mutation identified after an initial suspicion of HHT. Clinical, radiological and genetic characteristics were analysed. Results Among 21 patients with EPHB4, 15 had a liver imaging, including 7 with HHT-like abnormalities (2 female patients and 5 male patients, ages 43–69 years). Atypical epistaxis and telangiectases were noted in two cases each. They were significantly older than the eight patients with normal imaging (median: 51 vs 20 years, p<0.0006). The main hepatic artery was dilated in all the cases (diameter: 8–11mm). Six patients had hepatic telangiectases. All kind of shunts were described (arteriosystemic: five patients, arterioportal: two patients, portosystemic: three patients). The overall liver appearance was considered as typical of HHT in six cases. Six EPHB4 variants were classified as pathogenic and one as likely pathogenic, with no specific hot spot. Conclusion EPHB4 loss-of-function variants can be associated with HHT-like hepatic abnormalities and should be tested for atypical HHT presentations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.

Author

Arcani, Robin, Correard, Florian, Suchon, Pierre, Kaplanski, Gilles, Jean, Rodolphe, Cauchois, Raphael, Leprince, Marine, Arcani, Vincent, Seguier, Julie, De Sainte Marie, Benjamin, Andre, Baptiste, Koubi, Marie, Rossi, Pascal, Gayet, Stéphane, Gobin, Nirvina, Garrido, Victoria, Weiland, Joris, Jouve, Elisabeth, Couderc, Anne-Laure, and Villani, Patrick

Subjects
SARS-CoV-2, PROPENSITY score matching, CORONAVIRUS diseases, ANAKINRA, COVID-19
Abstract

Background: Tocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the efficacy of tocilizumab versus anakinra to guide the choice of the therapy in clinical practice. We aimed to compare the outcomes of COVID-19 patients treated with tocilizumab or anakinra. Methods: Our retrospective study was conducted in three French university hospitals between February 2021 and February 2022 and included all the consecutive hospitalized patients with a laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection assessed by RTPCR who were treated with tocilizumab or anakinra. A propensity score matching was performed to minimize confounding effects due to the non-random allocation. Results: Among 235 patients (mean age, 72 years; 60.9% of male patients), the 28-day mortality (29.4% vs. 31.2%, p = 0.76), the in-hospital mortality (31.7% vs. 33.0%, p = 0.83), the high-flow oxygen requirement (17.5% vs. 18.3%, p = 0.86), the intensive care unit admission rate (30.8% vs. 22.2%, p = 0.30), and the mechanical ventilation rate (15.4% vs. 11.1%, p = 0.50) were similar in patients receiving tocilizumab and those receiving anakinra. After propensity score matching, the 28-day mortality (29.1% vs. 30.4%, p = 1) and the rate of high-flow oxygen requirement (10.1% vs. 21.5%, p = 0.081) did not differ between patients receiving tocilizumab or anakinra. Secondary infection rates were similar between the tocilizumab and anakinra groups (6.3% vs. 9.2%, p = 0.44). Conclusion: Our study showed comparable efficacy and safety profiles of tocilizumab and anakinra to treat severe COVID-19. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients.

Author

Khitri, Mohamed-Yacine, Guedon, Alexis F., Georgin-Lavialle, Sophie, Terrier, Benjamin, Saadoun, David, Seguier, Julie, le Besnerais, Maelle, De Moreuil, Claire, Denis, Guillaume, Gerfaud-Valentin, Mathieu, Allain, Jean Sebastien, Maria, Alexandre, Bouillet, Laurence, Grobost, Vincent, Galland, Joris, Kosmider, Olivier, Dumont, Anael, Devaux, Mathilde, Subran, Benjamin, and Schmidt, Jean

Published
2022
Full Text
View/download PDF

17. Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review

Author

Roupie, Anne Laure, de Boysson, Hubert, Thietart, Sara, Carrat, Fabrice, Seguier, Julie, Terriou, Louis, Versini, Mathilde, Queyrel, Viviane, Groh, Matthieu, Benhamou, Ygal, Maurier, Francois, Decaux, Olivier, d'Aveni, Maud, Rossignol, Julien, Galland, Joris, Solary, Eric, Willems, Lise, Schleinitz, Nicolas, Ades, Lionel, Dellal, Azeddine, Samson, Maxime, Aouba, Achille, Fenaux, Pierre, Fain, Olivier, and Mekinian, Arsène

Published
2020
Full Text
View/download PDF

19. Paradoxical association between blood modular interferon signatures and quality of life in patients with systemic lupus erythematosus.

Author

Seguier, Julie, Jouve, Elisabeth, Bobot, Mickaël, Whalen, Elisabeth, Dussol, Bertrand, Gentile, Stéphanie, Burtey, Stéphane, Halfon, Philippe, Retornaz, Frédérique, Chaussabel, Damien, Chiche, Laurent, and Jourde-Chiche, Noémie

Subjects
*HEALTH status indicators, *HEALTH surveys, *INTERFERONS, *MENTAL health, *MULTIVARIATE analysis, *QUALITY of life, *QUESTIONNAIRES, *SYSTEMIC lupus erythematosus, *LUPUS nephritis, *GENE expression profiling, *DESCRIPTIVE statistics
Abstract

Objectives Blood transcriptomic IFN signature is a hallmark of SLE. The impaired health-related quality of life (HRQOL) observed in SLE is poorly related to disease activity. The aim of this study was to test how IFN signatures were associated with HRQOL in SLE patients. Methods Among consecutive patients, blood transcriptomic profiles were analysed with a modular framework comprising 3 IFN modules: M1.2, M3.4 and M5.12. Disease activity was evaluated by the SLEDAI score, and HRQOL was assessed with the SF-36 questionnaire, which includes eight domains: physical function, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health (MH) and physical component summary and mental component summary scores. Results A total of 57 SLE patients were evaluated, among whom 27 (47%) were clinically quiescent, 30 (53%) were flaring, and 19 (33%) had active lupus nephritis. All SF-36 domains were altered in SLE patients compared with the general French population (P < 0.0001). In multivariate analysis, taking into account flares, age, ethnicity, smoking and renal severity, social functioning was independently associated with the IFN score (P = 0.027). Analyses restrained to quiescent patients (n = 27) yielded greater associations between social functioning and the three IFN modules, and between MH and M3.4. Considering all quiescent visits (n = 51), the IFN score was independently correlated with social functioning (P = 0.022) and MH (P = 0.038). Conclusion This unexpected paradoxical association between IFN signature and some specific HRQOL domains argues against a pivotal role of IFNs in the persistently altered HRQOL of SLE patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

21. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.

Author

Meunier, Benoit, Rico, Audrey, Seguier, Julie, Boutiere, Clemence, Ebbo, Mikael, Harle, Jean Robert, Schleinitz, Nicolas, and Pelletier, Jean

Subjects
AUTOIMMUNE diseases, HEMOLYTIC anemia, MULTIPLE sclerosis, ALEMTUZUMAB, MONOCLONAL antibodies
Abstract

Background: Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Objective: To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male. Methods: Case report. Results: A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course. Conclusion: We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

22. 0082: Multimodality imaging in cardiac amyloidosis: respective contributions of echocardiography, MRI and scintigraphy

Author

Maysou, Laurie-Anne, Seguier, Julie, Fernandez, Rémi, Flavian, Antonin, Tessonnier, Laetitia, Saby, Ludivine, Michel, Nicolas, Hubert, Sandrine, Sumian, Marion, Salaun, Erwann, Renard, Sebastien, Avierinos, Jean-François, Verschueren, Annie, Franques, Jérôme, Mancini, Julien, Mundler, Olivier, Pouget, Jean, Jacquier, Alexis, Serratrice, Jacques, and Habib, Gilbert

Published
2015
Full Text
View/download PDF

23. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.

Author

Mekinian A, Biard L, Lorenzo D, Novikov PI, Salvarani C, Espitia O, Sciascia S, Michaud M, Lambert M, Hernández-Rodríguez J, Schleinitz N, Awisat A, Puechal X, Aouba A, Munoz Pons H, Smitienko I, Gaultier JB, Edwige LM, Benhamou Y, Perlat A, Jego P, Goulenok T, Sacre K, Lioger B, Hassold N, Broner J, Dufrost V, Sené T, Seguier J, Maurier F, Berthier S, Belot A, Frikha F, Denis G, Audemard-Verger A, Koné-Paut I, Humbert S, Woaye-Hune P, Tomelleri A, Baldissera EM, Kuwana M, Lo Gullo A, Mukuchyan V, Dellal A, Gaches F, Zeminsky P, Galli E, Alvarado M, Boiardi L, Muratore F, Vautier M, Campochiaro C, Moiseev S, Vieira M, Cacoub P, Fain O, and Saadoun D

Subjects
Humans, Adult, Retrospective Studies, Treatment Outcome, Takayasu Arteritis diagnosis, Takayasu Arteritis drug therapy, Antirheumatic Agents therapeutic use
Abstract

Objectives: In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients., Methods: We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019., Results: A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH <2 with less than 7.5 mg/day of prednisone) at 6 months was evidenced in 69% of TAK patients, of whom 57 (70%) and 11 (69%) patients were on intravenous and SC tocilizumab, respectively (p=0.95). The factors associated with complete response to tocilizumab at 6 months in multivariate analysis, only age <30 years (OR 2.85, 95% CI 1.14 to 7.12; p=0.027) and time between TAK diagnosis and tocilizumab initiation (OR 1.18, 95% CI 1.02 to 1.36; p=0.034). During the median follow-up of 30.1 months (0.4; 105.8) and 10.8 (0.1; 46.4) (p<0.0001) in patients who received tocilizumab in intravenous and SC forms, respectively, the risk of relapse was significantly higher in TAK patients on SC tocilizumab (HR=2.55, 95% CI 1.08 to 6.02; p=0.033). The overall cumulative incidence of relapse at 12 months in TAK patients was at 13.7% (95% CI 7.6% to 21.5%), with 10.3% (95% CI 4.8% to 18.4%) for those on intravenous tocilizumab vs 30.9% (95% CI 10.5% to 54.2%) for patients receiving SC tocilizumab. Adverse events occurred in 14 (15%) patients on intravenous route and in 2 (11%) on SC tocilizumab., Conclusion: In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

24. Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients.

Author

Mekinian A, Biard L, Dagna L, Novikov P, Salvarani C, Espitia O, Sciascia S, Michaud M, Lambert M, Hernández-Rodríguez J, Schleinitz N, Awisat A, Puéchal X, Aouba A, Munoz Pons H, Smitienko I, Gaultier JB, Le Mouel E, Benhamou Y, Perlat A, Jego P, Goulenok T, Sacre K, Lioger B, Hassold N, Broner J, Dufrost V, Sene T, Seguier J, Maurier F, Berthier S, Belot A, Frikha F, Denis G, Audemard-Verger A, Kone Pault I, Humbert S, Woaye-Hune P, Tomelleri A, Baldissera E, Kuwana M, Lo Gullo A, Gaches F, Zeminsky P, Galli E, Alvarado M, Boiardi L, Muratore F, Vautier M, Campochiaro C, Moiseev S, Cacoub P, Fain O, and Saadoun D

Subjects
Adult, Antibodies, Monoclonal, Humanized, Female, Humans, Recurrence, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Takayasu Arteritis complications, Takayasu Arteritis drug therapy, Tumor Necrosis Factor-alpha
Abstract

Objective: To assess the safety and the efficacy of TNF-α antagonists and tocilizumab in patients with Takayasu arteritis (TAK)., Methods: A total of 209 patients with TAK [median age 29 years (interquartile range 7-62)], 186 (89%) females] were included. They received either TNF-α antagonists [n = 132 (63%) with 172 lines; infliximab (n = 109), adalimumab (n = 45), golimumab (n = 8), certolizumab (n = 6) and etanercept (n = 5)] or tocilizumab [n = 77 (37%) with 121 lines; i.v. and s.c. in 95 and 26 cases, respectively]., Results: A complete response at 6 months was evidenced in 101/152 (66%) patients on TNF-α antagonists and 75/107 (70%) patients on tocilizumab. Age ≥30 years [odds ratio 2.09 (95% CI 1.09, 3.99)] was associated with complete response, whereas vascular signs [OR 0.26 (95% CI 0.1, 0.65)], baseline prednisone ≥20 mg/day [OR 0.51 (95% CI 0.28, 0.93)] were negatively associated with the complete response to TNF-α antagonists or tocilizumab. During a median follow-up of 36 months, 103 relapses were noted. Supra-aortic branches and thoracic aorta involvement [HR 2.44 (95% CI 1.06, 5.65) and 3.66 (1.18, 11.4), respectively] and systemic signs at baseline [HR 2.01 (95% CI 1.30, 3.11)] were significantly associated with relapse. The cumulative incidence of treatment discontinuation and relapse were similar in TNF-α antagonists and tocilizumab. Fifty-eight (20%) adverse effects occurred on biologic targeted therapies [37 (21%) on TNF-α antagonists and 21 (17%) on tocilizumab (P = 0.4), respectively]., Conclusion: This large multicentre study shows high efficacy of biologic targeted treatments in refractory TAK. Efficacy, relapse and drug retention rate were equivalent with TNF-α antagonists and tocilizumab., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

25. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.

Author

Jachiet V, Moulis G, Hadjadj J, Seguier J, Laribi K, Schleinitz N, Vey N, Sacre K, Godeau B, Beyne-Rauzy O, Bouvet R, Broner J, Brun N, Comont T, Gaudin C, Lambotte O, Le Clech L, Peterlin P, Roy-Peaud F, Salvado C, Versini M, Isnard F, Kahn JE, Gobert D, Adès L, Fenaux P, Fain O, and Mekinian A

Subjects
Humans, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic complications, Leukemia, Myelomonocytic, Chronic diagnosis, Leukemia, Myelomonocytic, Chronic therapy, Myelodysplastic Syndromes complications, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes therapy, Purpura, Thrombocytopenic, Idiopathic diagnosis, Purpura, Thrombocytopenic, Idiopathic etiology, Purpura, Thrombocytopenic, Idiopathic therapy, Thrombocytopenia
Abstract

Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessing this association are missing. Whether such patients have a particular phenotype and require particular management is unclear. This study analyzes the clinical spectrum, outcome and therapeutic management of patients with ITP associated with MDS or CMML, in comparison (i) to patients with primary ITP without MDS/CMML and (ii) to patients with MDS/CMML without ITP. Forty-one MDS/CMML-associated ITP patients were included, with chronic ITP in 26 (63%) patients, low-risk myelodysplasia in 30 (73%) patients and CMML in 24 (59%) patients. An associated autoimmune disease was noted in 10 (24%) patients. In comparison to primary ITP patients, MDS/CMML-associated ITP patients had a higher occurrence of severe bleeding despite similar platelet counts at diagnosis. First-line treatment consisted of glucocorticoids (98%) and intravenous immunoglobulin (IVIg) (56%). Response achievement with IVIg was more frequent in primary ITP than in MDS/CMML-associated ITP patients. Response rates to second-line therapies were not statistically different between primary ITP and MDS/CMMLassociated ITP patients. Ten percent (n=4) of patients with MDS/CMML-associated ITP had multirefractory ITP versus none in primary ITP controls. After a median follow-up of 60 months, there was no difference in overall survival between MDS/CMML-associated ITP and primary ITP patients. Leukemia-free-survival was significantly better in MDS/CMMLassociated ITP patients than in MDS/CMML without ITP MDS/CMML-associated ITP have a particular outcome with more severe bleeding and multirefractory profile than primary ITP, similar response profile to primary ITP therapy except for IVIg, and less progression toward acute myeloid leukemia than MDS/CMML without ITP.

Published
2021
Full Text
View/download PDF

26. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.

Author

Meunier B, Rico A, Seguier J, Boutiere C, Ebbo M, Harle JR, Schleinitz N, and Pelletier J

Subjects
Adult, Humans, Male, Alemtuzumab adverse effects, Anemia, Hemolytic, Autoimmune chemically induced, Immunologic Factors adverse effects, Multiple Sclerosis, Relapsing-Remitting drug therapy
Abstract

Background: Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS)., Objective: To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male., Methods: Case report., Results: A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course., Conclusion: We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results